Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 1333.

https://doi.org/10.1182/blood.V120.21.1333.1333

Published: 2012

Journal Articles

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 531.

https://doi.org/10.1182/blood.V120.21.531.531

Published: 2012

Journal Articles

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3737.

https://doi.org/10.1182/blood.V120.21.3737.3737

Published: 2012

Journal Articles

Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies

Tetsuzo Tauchi, M.D., Seiichiro Katagiri, M.D., Seiichi Okabe, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 2482.

https://doi.org/10.1182/blood.V118.21.2482.2482

Published: 2011

Journal Articles

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

Itaru Kuroda, MD, PhD, Takeshi Inukai, MD, PhD, Xiaochun Zhang, MD, PhD, Jiro Kikuchi, Yusuke Furukawa, Atsushi Nemoto, MD, PhD, Koshi Akahane, MD, PhD, Kinuko Hirose, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Hideo Yagita, PhD, Tetsuzo Tauchi, M.D., Yasuhiro Maeda, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 2740.

https://doi.org/10.1182/blood.V118.21.2740.2740

Published: 2011

Journal Articles

Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib

Seiichiro Katagiri, M.D., Tetsuzo Tauchi, M.D., Seiichi Okabe, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2011) 118 (21): 63.

https://doi.org/10.1182/blood.V118.21.63.63

Published: 2011

Journal Articles

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

Atsushi Nemoto, MD, PhD, Takeshi Inukai, MD, PhD, Koshi Akahane, MD, PhD, Hiroko Honna- Oshiro, MD, PhD, Kumiko Goi, MD, PhD, Keiko Kagami, Yasuhiro Maeda, MD, PhD, Tetsuzo Tauchi, M.D., Shinya Kimura, MD, PhD, Kanji Sugita, MD, PhD

Blood (2011) 118 (21): 1511.

https://doi.org/10.1182/blood.V118.21.1511.1511

Published: 2011

Journal Articles

GDC-0449, the Small Molecule Inhibitor of Hedgehog-Gli Pathway for the Treatment of BCR-ABL Positive Leukemia Cells and In Combination with Dasatinib

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Kazuma Ohyashiki, MD, PhD

Blood (2010) 116 (21): 2136.

https://doi.org/10.1182/blood.V116.21.2136.2136

Published: 2010

Journal Articles

Activity of the Histone Deacetylase Inhibitor, Vorinostat, Against BCR-ABL Positive Leukemia Cells with Random Mutagenesis and In Combination with Nilotinib

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Eishi Ashihara, MD, PhD, Shinya Kimura, MD, PhD, Taira Maekawa, MD, DMSci, Kazuma Ohyashiki, MD, PhD

Blood (2010) 116 (21): 4460.

https://doi.org/10.1182/blood.V116.21.4460.4460

Published: 2010

Journal Articles

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Tetsuzo Tauchi, M.D., Seiichi Okabe, M.D., Eishi Ashihara, M.D., Shinya Kimura, M.D., Taira Maekawa, M.D., Kazuma Ohyashiki, M.D.

Blood (2010) 116 (21): 595.

https://doi.org/10.1182/blood.V116.21.595.595

Published: 2010

Journal Articles

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Tetsuzo Tauchi, M.D., Masahiro Kizaki, M.D., Shinichiro Okamoto, M.D., Hideo Tanaka, M.D., Mitsune Tanimoto, M.D., Koiti Inokuchi, M.D., Tohru Murayama, M.D., Yoshio Saburi, M.D., Masayuki Hino, M.D., Mitsuru Tsudo, M.D., Taizo Shimomura, M.D., Yasushi Isobe, M.D., Kazuo Oshimi, MD, Kazuo Dan, M.D., Kazuma Ohyashiki, M.D., Yasuo Ikeda, M.D.

Blood (2010) 116 (21): 2287.

https://doi.org/10.1182/blood.V116.21.2287.2287

Published: 2010

Journal Articles

Depsipeptide (FK228) Preferntially Induces Apoptosis in Acute T-Cell Leukemia Cell Lines Mediated by CD45 and Src Kinase.

Seiichi Okabe, MD, PhD, Tetsuzo Tauchi, M.D., Ph.D., Hal E. Broxmeyer, Ph.D., Kazuma Ohyashiki, M.D., Ph.D.

Blood (2006) 108 (11): 4468.

https://doi.org/10.1182/blood.V108.11.4468.4468

Published: 2006

Journal Articles

Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells.

Seiichi Okabe, MD, PhD, Tetsuzo Tauchi, M.D., Ph.D., Hal E. Broxmeyer, Ph.D., Kazuma Ohyashiki, M.D., Ph.D.

Blood (2006) 108 (11): 1386.

https://doi.org/10.1182/blood.V108.11.1386.1386

Published: 2006

Journal Articles

Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells.

Goro Sashida, M.D., Tetsuzo Tauchi, M.D., Masahiko Sumi, M.D., Akihiro Nakajima, M.D., Junko H. Ohyashiki, M.D., Kazuma Ohyashiki, M.D.

Blood (2004) 104 (11): 4339.

https://doi.org/10.1182/blood.V104.11.4339.4339

Published: 2004

NARROW

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Targeting the Hedgehog Signaling Pathway Limits the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies

BCR-ABL Regulates Death Receptor Expression for TNF-Related Apoptosis-Inducing Ligand (TRAIL) in Philadelphia Chromosome-Positive Leukemia

Targeting the Hedgehog Signaling Pathway in Therapy-Resistant BCR-ABL1 Positive Leukemia with Ponatinib

PD0332991, a CDK4/6 Inhibitor, Has An Anti-Leukemic Activity Against Lymphoid Crisis of CML and Ph+ALL Even with T315I Mutation in BCR-Abl; in Vitro Analysis

GDC-0449, the Small Molecule Inhibitor of Hedgehog-Gli Pathway for the Treatment of BCR-ABL Positive Leukemia Cells and In Combination with Dasatinib

Activity of the Histone Deacetylase Inhibitor, Vorinostat, Against BCR-ABL Positive Leukemia Cells with Random Mutagenesis and In Combination with Nilotinib

Combined Effects of the Hedgehog Pathway Inhibitor LDE225 and Nilotinib In a Random Mutagenesis Screen

Seven-Year Follow-up of Patients Receiving Imatinib for the Treatment of Chronic Myelogenous Leukemia by the TARGET System

Depsipeptide (FK228) Preferntially Induces Apoptosis in Acute T-Cell Leukemia Cell Lines Mediated by CD45 and Src Kinase.

Mechanism of Drug Resistance to Dasatinib (BMS-354825) and Imatinib in Chronic Myelogenous Leukemia Cells.

Specific Inhibition of hTERT by shRNA Sensitizes for Imatinib Mesylate in BCR-ABL-Positive Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only